- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Introduction: Background on Hospital Readmissions
During the introduction to this one-on-one interview series, Arthur Garson, Jr, MD, MPH, director of the Center for Health Policy at the University of Virginia, discusses rates of hospital readmissions following transitions between healthcare settings and highlights a Centers for Medicare & Medicaid Services (CMS) program designed to reduce the number of readmissions.
Dr Garson, Jr, reviews the number of unnecessary hospital readmissions within 30 days of discharge and notes that nearly 20% of Medicare patients are readmitted.
However, he explains that the number of readmissions has recently decreased due to penalties implemented by a CMS program.
Dr Garson, Jr, emphasizes the importance of implementing programs that target readmissions such as the program designed by the CMS, and suggests that this program represents a step in the right direction toward reducing or preventing unnecessary hospital readmissions.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
March 14th 2025Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.
Read More
